UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

Cancer, 2017-02, Vol.123 (4), p.592-599

2017

Volltextzugriff (PDF)

The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‐specific Antigen‐era

International journal of cancer, 2015-12, Vol.137 (12), p.2795-2802

2015

Volltextzugriff (PDF)

Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study

Annals of oncology, 2016-03, Vol.27 (3), p.460-466

2016

Volltextzugriff (PDF)

PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?

European journal of nuclear medicine and molecular imaging, 2016-07, Vol.43 (8), p.1418-1424

2016

Volltextzugriff (PDF)

Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate‐specific antigen (PSA)‐based detection of prostate cancer in men without prior biopsies

BJU international, 2015-03, Vol.115 (3), p.381-388

2015

Volltextzugriff (PDF)

Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

European journal of nuclear medicine and molecular imaging, 2016-03, Vol.43 (3), p.397-403

2016

Volltextzugriff (PDF)

Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-Analysis

European urology, 2005-09, Vol.48 (3), p.386-399

2005

Volltextzugriff (PDF)

Simultaneous Detection of Dual Prostate Specific Antigens Using Surface-Enhanced Raman Scattering-Based Immunoassay for Accurate Diagnosis of Prostate Cancer

ACS nano, 2017-05, Vol.11 (5), p.4926-4933

2017

Volltextzugriff (PDF)

Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis)

Andrologia, 2015-04, Vol.47 (3), p.328-332

2015

Volltextzugriff (PDF)

Combination of prostate imaging reporting and data system (PI‐RADS) score and prostate‐specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients

BJU international, 2017-02, Vol.119 (2), p.225-233

2017

Volltextzugriff (PDF)

Early Detection of Prostate Cancer: European Association of Urology Recommendation

European urology, 2013-09, Vol.64 (3), p.347-354

2013

Volltextzugriff (PDF)

The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Annals of epidemiology, 2016, Vol.26 (1), p.36-42.e2

2016

Volltextzugriff (PDF)

Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials

Radiotherapy and oncology, 2013-11, Vol.109 (2), p.217-221

2013

Volltextzugriff (PDF)

The percentage of prostate‐specific antigen (PSA) isoform [–2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years

BJU international, 2016-01, Vol.117 (1), p.72-79

2016

Volltextzugriff (PDF)

Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects

Advances in experimental medicine and biology, 2015, Vol.867, p.93

2015

Volltextzugriff (PDF)

Biomarkers for prostate cancer: prostate-specific antigen and beyond

Clinical chemistry and laboratory medicine, 2020-03, Vol.58 (3), p.326-339

Duffy, Michael J

2020

Volltextzugriff (PDF)

Obesity, risk of biochemical recurrence, and prostate‐specific antigen doubling time after radical prostatectomy: results from the SEARCH database

BJU international, 2019-07, Vol.124 (1), p.69-75

2019

Volltextzugriff (PDF)

Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients

Cancer letters, 2017-09, Vol.403, p.318-329

2017

Volltextzugriff (PDF)

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

The Prostate, 2016-10, Vol.76 (14), p.1257-1270

2016

Volltextzugriff (PDF)

Validation of prostate‐specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries

Cancer, 2017-02, Vol.123 (4), p.697-703

2017

Volltextzugriff (PDF)

Prostate cancer: measuring PSA

Internal medicine journal, 2014-05, Vol.44 (5), p.433-440

2014

Volltextzugriff (PDF)

An electrochemical biosensor to simultaneously detect VEGF and PSA for early prostate cancer diagnosis based on graphene oxide/ssDNA/PLLA nanoparticles

Biosensors & bioelectronics, 2017-03, Vol.89 (Pt 1), p.598-605

2017

Volltextzugriff (PDF)

Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer

European journal of cancer (1990), 2021-11, Vol.157, p.259-267

2021

Volltextzugriff (PDF)

Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer

BJU international, 2009-12, Vol.104 (11), p.1592-1598

2009

Volltextzugriff (PDF)

1 – 25 von 1.023

Suche als RSS-Feed

Aktive Filter

ThemaProstatic Neoplasms - Blood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(985)
Mit Volltextzugriff
(905)

Publikationsform

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Male
(1.023)
Humans
(1.022)
Prostate-Specific Antigen - Blood
(951)
Science & Technology
(934)
Life Sciences & Biomedicine
(930)
Prostate Cancer
(753)
Aged
(708)
Middle Aged
(691)
Psa
(526)
Prostatic Neoplasms - Pathology
(419)
Urology & Nephrology
(415)
Oncology
(404)
Biological And Medical Sciences
(375)
Medical Sciences
(371)
Prostatic Neoplasms - Diagnosis
(359)
Nephrology. Urinary Tract Diseases
(297)
Aged, 80 And Over
(293)
Tumors Of The Urinary System
(284)
Urinary Tract. Prostate Gland
(282)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Bju International
(121)
International Journal Of Radiation Oncology, Biology, Physics
(72)
European Urology
(68)
Anticancer Research
(53)
The Prostate
(49)
Urologic Oncology
(30)
World Journal Of Urology
(29)
International Journal Of Urology
(24)
Brachytherapy
(21)
Cancer
(19)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‐specific Antigen‐era

Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study

PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?

Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate‐specific antigen (PSA)‐based detection of prostate cancer in men without prior biopsies

Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-Analysis

Simultaneous Detection of Dual Prostate Specific Antigens Using Surface-Enhanced Raman Scattering-Based Immunoassay for Accurate Diagnosis of Prostate Cancer

Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis)

Combination of prostate imaging reporting and data system (PI‐RADS) score and prostate‐specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients

Early Detection of Prostate Cancer: European Association of Urology Recommendation

The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials

The percentage of prostate‐specific antigen (PSA) isoform [–2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years

Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects

Biomarkers for prostate cancer: prostate-specific antigen and beyond

Obesity, risk of biochemical recurrence, and prostate‐specific antigen doubling time after radical prostatectomy: results from the SEARCH database

Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

Validation of prostate‐specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries

Prostate cancer: measuring PSA

An electrochemical biosensor to simultaneously detect VEGF and PSA for early prostate cancer diagnosis based on graphene oxide/ssDNA/PLLA nanoparticles

Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer

Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer

Aktive Filter

Suchergebnisse filtern